Zivo Bioscience Moves Forward With Planned Pilot Production and Validation Studies Upon Q1 2016 $1M Funding Advance From Lead Investor

KEEGO HARBOR, Mich., March 03, 2016 -- Zivo Bioscience, Inc. (OTCQB:ZIVO) announced today that to date it has received $1 million in Q1 2016 funding advances from lead investor and primary lender HEP Investments, LLC, which allows the Company to immediately move forward with various projects and studies focused on commercialization of its proprietary algal products.

“We’re happy to have negotiated favorable terms and funding levels to put into motion the plans we developed late last year,” states ZIVO Bioscience CEO Andrew Dahl. “With these monies in place, we can kick off some of our highest priority activities that should place us in a favorable position with potential licensees and customers.”

 The Company will immediately activate its bovine feed additive development program, which ranges from commercial pilot production to post-processing, encapsulation and pelletizing.

“Activating the R&D plan means we can move toward our first goal of fielding a bovine feed additive both here in the US and abroad,” states Dr. Amy Steffek, Director of Research & Development. “The first phase of the plan involves preparation of product in sufficient quantity for additional safety testing as an orally-administered product to improve milking productivity on a herd-wide basis. This same work is also applicable to concluding our previous studies to optimize recovery from bovine mastitis, with the potential to offer organic and production dairy producers a natural, antibiotic-free option to control mastitis appropriate to both settings.”

The Company will continue its successful bovine mastitis research as it attracts more capital funding from various sources throughout 2016. ZIVO principals have expressed optimism at the near-term prospect of additional funding to propel the Company toward licensing agreements in the coming year.

“We’ve reached a stage in development and validation where potential customers and partners can begin to see how this all comes together in the form of a licensing platform,” states CEO Dahl. “The markets, the applications, the regulations and the manufacturing options have begun to coalesce, and we believe the momentum is going to increase from here forward.”

About ZIVO Bioscience, Inc.

ZIVO Bioscience, Inc. (OTCQB:ZIVO) is a Michigan-based biotech company engaged in the investigation of the health benefits of bioactive compounds derived from its proprietary algal cultures, and the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as biologically derived and synthetic candidates for medicinal and pharmaceutical applications in humans and animals, specifically focused on autoimmune and inflammatory response modulation.

Safe Harbor Statement

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.

Contact:

Angie Chunovich
Management Liaison
(248) 452 9866

ZIVO Bioscience, Inc.     
[email protected]